Decreased plasma orexin-A levels in obese individuals
This is lower than the approximately 39% GI event rate seen in clinical trials at the equivalent injectable initiation dose, likely because the daily peak concentration is lower than the weekly injection peak
Additionally, atherosclerotic plaques can be destabilized by systemic inflammatory response which happens simultaneously with pro-inflammatory and pro-oxidative effects of SARS-CoV-2, thereby giving rise to acute coronary syndrome and ischemic heart disease among COVID-19 patients
and treatment outcomes involving GLP-1RAs and control groups, including changes in creatinine, eGFR, UPCR or 24-hour urine protein excretion, blood glucose or HbA1c, BP, body weight or BMI, tacrolimus levels, incidence of CV events, all-cause mortality and any adverse events (including allograft rejection)
If you specifically want an FDA-approved finished product and nothing else, confirm this option during your consultation or explore platforms that exclusively dispense branded medications